Abiopharma

(90% Positive) INHIBRX, INC. (INBX) Announces Clinical Development Update

(99% Neutral) Repare Therapeutics Inc. (RPTX) Announces New Board Appointment

(30% Negative) Cellectis (CLLS) Files Form 6-K

(99% Neutral) Neoleukin Therapeutics, Inc. (NLTX) Announces Regulatory Update

(10% Negative) AEROVATE THERAPEUTICS, INC. (AVTE) Announces Delay in enthusiasm Trials for our Phase 2b/Phase 3 trial Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(19% Negative) SESEN BIO, INC. (SESN) Announces Regulatory Update

(30% Negative) Century Therapeutics, Inc. (IPSC) Reports Q2 2022 Financial Results

(99% Neutral) HUTCHMED DRC (HCM) Announces 2022 Annual General Meeting

(10% Negative) PASSAGE BIO, INC. (PASG) Reports Q2 2022 Financial Results

(10% Negative) Instil Bio, Inc. (TIL) Reports Q2 2022 Financial Results